Multi-functional nanocarriers to overcome tumor drug resistance

Abstract

The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance modulators (e.g., with P-glycoprotein substrates), agents that regulate intracellular pH, agents that lower the apoptotic threshold (e.g., with ceramide), or in combination with energy delivery (e.g., sound, heat, and light) to enhance the effectiveness of anticancer agents in refractory tumors. In preclinical studies, the use of multi-functional nanocarriers has shown significant promise in enhancing cancer therapy, especially against MDR tumors.

Graphene-Based Anticancer Nanosystem and Its Biosafety Evaluation Using a Zebrafish Model

“…1,2 However, these drug carriers are often associated with drawbacks including undesirable burst drug release and premature drug leaking due to their limited stability. Very recently, graphene materials were shown to be capable of loading aromatic anticancer drugs such as doxorubicin (DOX) and camptothecin (CPT) with ultrahigh efficiency.…”

Antitoxic and antioxidant effects of N-stearoylethanolamin in the content of nanocomposite complex with doxorubicin in organs of mice with Lewis carcinoma

“…Деякі з цих проблем можуть бути подолані шляхом роз-робки адекватних систем доставки лікарських засобів [4]. Такі системи можуть забезпечити вплив на пухлини протягом тривалого періоду часу внаслідок їх специфічної взаємодії з мембраною злоякісних клітин, не пошко-джуючи при цьому умовно нормальні клітини [5]. Через високу токсичність протипухлин-них препаратів дуже важливим є пошук спо-лук, які б могли зменшувати побічні ефекти хіміотерапії.…”

Multidrug Resistance in Cancer Circumvented Using a Cytosolic Drug Reservoir

“…The uncertainties led to unsuccessful application of the inhibitors or siRNA on clinical therapies. In fact, therapies that target one MDR pathway were found to enhance the ability of cancer cells to adapt and develop other drug resistance pathways such as alternating efflux transporters 2, 3, 4, 5, 6, 7…”